Clovis Oncology (CLVS) Announces Q3 2016 Operating Results And Corporate Update
11/4/2016 10:57:21 AM
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2016, and provided an update on the Company’s clinical development programs and regulatory outlook for the remainder of 2016.
“We are actively preparing for a U.S. launch of rucaparib pending FDA’s decision on our NDA, and we have completed our Marketing Authorization Application submission seeking European approval for rucaparib,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology.
comments powered by